---
annotation-target: cancers-14-02008.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-07T05:11:40.756Z","updated":"2022-09-07T05:11:40.756Z","document":{"title":"Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma","link":[{"href":"urn:x-pdf:ae958cdba61ade011eb31b4975d42765"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf"}],"documentFingerprint":"ae958cdba61ade011eb31b4975d42765"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf","selector":[{"type":"TextPositionSelector","start":2992,"end":3198},{"type":"TextQuoteSelector","exact":"Our study comparedthe potential of radiomics-based machine learning and 3D deep learning models as non-invasivebiomarkers to risk-stratify MCL patients, thus promoting precision imaging in clinical oncology","prefix":"he early prediction of relapse. ","suffix":".Abstract: Mantle cell lymphoma "}]}]}
>```
>%%
>*%%PREFIX%%he early prediction of relapse.%%HIGHLIGHT%% ==Our study comparedthe potential of radiomics-based machine learning and 3D deep learning models as non-invasivebiomarkers to risk-stratify MCL patients, thus promoting precision imaging in clinical oncology== %%POSTFIX%%.Abstract: Mantle cell lymphoma*
>%%LINK%%[[#^9rq3jxs8sfr|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^9rq3jxs8sfr


>%%
>```annotation-json
>{"created":"2022-09-07T05:12:50.264Z","updated":"2022-09-07T05:12:50.264Z","document":{"title":"Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma","link":[{"href":"urn:x-pdf:ae958cdba61ade011eb31b4975d42765"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf"}],"documentFingerprint":"ae958cdba61ade011eb31b4975d42765"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf","selector":[{"type":"TextPositionSelector","start":5454,"end":6062},{"type":"TextQuoteSelector","exact":"Most MCL patients present with aggressive diseasein an advanced stage (Stage III-IV); however, a subset of patients exhibit an indolentevolution [7]. As a result, the World Health Organization (WHO) updated the classificationof MCL in 2017, describing two main subtypes, “classical MCL” and “indolent leukemicnon-nodal/smouldering MCL”, with significant differences in the molecular characteristics,clinical features and prognosis [8]. According to follow-up studies, early identification ofhigh-risk patients may modify their therapeutic management, reduce unnecessary toxicity,and improve prognosis [9–12].","prefix":"eralised lymphadenopathy [3–6]. ","suffix":"As initial staging, the ESMO gui"}]}]}
>```
>%%
>*%%PREFIX%%eralised lymphadenopathy [3–6].%%HIGHLIGHT%% ==Most MCL patients present with aggressive diseasein an advanced stage (Stage III-IV); however, a subset of patients exhibit an indolentevolution [7]. As a result, the World Health Organization (WHO) updated the classificationof MCL in 2017, describing two main subtypes, “classical MCL” and “indolent leukemicnon-nodal/smouldering MCL”, with significant differences in the molecular characteristics,clinical features and prognosis [8]. According to follow-up studies, early identification ofhigh-risk patients may modify their therapeutic management, reduce unnecessary toxicity,and improve prognosis [9–12].== %%POSTFIX%%As initial staging, the ESMO gui*
>%%LINK%%[[#^bt9tn8dpwv|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^bt9tn8dpwv


>%%
>```annotation-json
>{"created":"2022-09-07T05:14:17.653Z","updated":"2022-09-07T05:14:17.653Z","document":{"title":"Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma","link":[{"href":"urn:x-pdf:ae958cdba61ade011eb31b4975d42765"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf"}],"documentFingerprint":"ae958cdba61ade011eb31b4975d42765"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf","selector":[{"type":"TextPositionSelector","start":6062,"end":6376},{"type":"TextQuoteSelector","exact":"As initial staging, the ESMO guidelines recommend performing a contrast-enhancedcomputed tomography (CT) scan of the neck, thorax, abdomen and pelvis as treatmentdiffers depending on the stage of the disease [7]. A PET/CT scan is especially recommendedin the rare limited stages I/II before localised radiotherapy,","prefix":"ty,and improve prognosis [9–12].","suffix":" although reimbursement bythe do"}]}]}
>```
>%%
>*%%PREFIX%%ty,and improve prognosis [9–12].%%HIGHLIGHT%% ==As initial staging, the ESMO guidelines recommend performing a contrast-enhancedcomputed tomography (CT) scan of the neck, thorax, abdomen and pelvis as treatmentdiffers depending on the stage of the disease [7]. A PET/CT scan is especially recommendedin the rare limited stages I/II before localised radiotherapy,== %%POSTFIX%%although reimbursement bythe do*
>%%LINK%%[[#^mllhe9pwry9|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^mllhe9pwry9


>%%
>```annotation-json
>{"created":"2022-09-07T05:14:35.928Z","updated":"2022-09-07T05:14:35.928Z","document":{"title":"Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma","link":[{"href":"urn:x-pdf:ae958cdba61ade011eb31b4975d42765"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf"}],"documentFingerprint":"ae958cdba61ade011eb31b4975d42765"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf","selector":[{"type":"TextPositionSelector","start":6624,"end":6960},{"type":"TextQuoteSelector","exact":"Novel therapeutic options are constantly evolving, but until today, management ofMCL is challenging due to its pattern of resistance, early relapse and poor long-termsurvival [13]. Despite improvements in remission durations, MCL is regarded as anincurable malignancy, despite the novel drug strategies developed in recent years [14,15]","prefix":"nd the heterogeneity of MCL [7].","suffix":".The “mantle cell lymphoma Inter"}]}]}
>```
>%%
>*%%PREFIX%%nd the heterogeneity of MCL [7].%%HIGHLIGHT%% ==Novel therapeutic options are constantly evolving, but until today, management ofMCL is challenging due to its pattern of resistance, early relapse and poor long-termsurvival [13]. Despite improvements in remission durations, MCL is regarded as anincurable malignancy, despite the novel drug strategies developed in recent years [14,15]== %%POSTFIX%%.The “mantle cell lymphoma Inter*
>%%LINK%%[[#^0m2tnsirkco|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^0m2tnsirkco


>%%
>```annotation-json
>{"created":"2022-09-07T05:15:45.030Z","updated":"2022-09-07T05:15:45.030Z","document":{"title":"Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma","link":[{"href":"urn:x-pdf:ae958cdba61ade011eb31b4975d42765"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf"}],"documentFingerprint":"ae958cdba61ade011eb31b4975d42765"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf","selector":[{"type":"TextPositionSelector","start":6961,"end":7300},{"type":"TextQuoteSelector","exact":"The “mantle cell lymphoma International Prognostic Index (MIPI)”, based on age,ECOG performance status, lactate dehydrogenase and leukocyte count, assigns patients tolow-risk, intermediate-risk and high-risk groups with 5-year survival rates of 60%, medianoverall survival of 51 months or median overall survival OS 29 months, respectively","prefix":"veloped in recent years [14,15].","suffix":" [16].Furthermore, the cell prol"}]}]}
>```
>%%
>*%%PREFIX%%veloped in recent years [14,15].%%HIGHLIGHT%% ==The “mantle cell lymphoma International Prognostic Index (MIPI)”, based on age,ECOG performance status, lactate dehydrogenase and leukocyte count, assigns patients tolow-risk, intermediate-risk and high-risk groups with 5-year survival rates of 60%, medianoverall survival of 51 months or median overall survival OS 29 months, respectively== %%POSTFIX%%[16].Furthermore, the cell prol*
>%%LINK%%[[#^s7cwnvfvknf|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^s7cwnvfvknf


>%%
>```annotation-json
>{"created":"2022-09-07T05:17:15.084Z","updated":"2022-09-07T05:17:15.084Z","document":{"title":"Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma","link":[{"href":"urn:x-pdf:ae958cdba61ade011eb31b4975d42765"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf"}],"documentFingerprint":"ae958cdba61ade011eb31b4975d42765"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf","selector":[{"type":"TextPositionSelector","start":25461,"end":25475},{"type":"TextQuoteSelector","exact":"e  Weka  Toolk","prefix":"the  GNU  General Public  Licens","suffix":"it  (version  3.8, University of"}]}]}
>```
>%%
>*%%PREFIX%%the  GNU  General Public  Licens%%HIGHLIGHT%% ==e  Weka  Toolk== %%POSTFIX%%it  (version  3.8, University of*
>%%LINK%%[[#^hq5w5tijkr|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^hq5w5tijkr


>%%
>```annotation-json
>{"created":"2022-09-07T05:20:14.955Z","updated":"2022-09-07T05:20:14.955Z","document":{"title":"Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma","link":[{"href":"urn:x-pdf:ae958cdba61ade011eb31b4975d42765"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf"}],"documentFingerprint":"ae958cdba61ade011eb31b4975d42765"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/cancers-14-02008.pdf","selector":[{"type":"TextPositionSelector","start":37419,"end":37595},{"type":"TextQuoteSelector","exact":"3D Squeeze-and-Excitation ResNet 50 (SEResNet50): We used the 3D Squeeze-and-Excitation ResNet SEResNet50 [82] from Monai [Medical Open Network for ArtificialIntelligence MONAI","prefix":"ved vanishing gradient problems.","suffix":" https://monai.io/; last accesse"}]}]}
>```
>%%
>*%%PREFIX%%ved vanishing gradient problems.%%HIGHLIGHT%% ==3D Squeeze-and-Excitation ResNet 50 (SEResNet50): We used the 3D Squeeze-and-Excitation ResNet SEResNet50 [82] from Monai [Medical Open Network for ArtificialIntelligence MONAI== %%POSTFIX%%https://monai.io/; last accesse*
>%%LINK%%[[#^zy8kvr8ku9o|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^zy8kvr8ku9o
